key: cord-1005879-kd560qmr
authors: Kotze, Paulo Gustavo; Peyrin-Biroulet, Laurent; Danese, Silvio
title: Balancing risks and benefits in inflammatory bowel disease patients during the COVID-19 pandemic
date: 2020-05-15
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.04.075
sha: 7dacff7ad57b7ce2989edda271512e9bab454cc0
doc_id: 1005879
cord_uid: kd560qmr

nan

P.G.K has been a lecturer for AbbVie, Janssen, Pfizer and Takeda and is a member of the advisory board of AbbVie, Pfizer and Takeda. L.P.-B. has received consulting fees from AbbVie, Amgen, Biogaran, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Ferring, Genentech, HAC Pharma, Hospira, Index Pharmaceuticals, Janssen, Lilly, Merck, Mitsubishi, Norgine, Pfizer, Pharmacosmos, Pilege, Sandoz, Takeda, Therakos, Tillotts, UCB Pharma and Vifor and lecture fees from AbbVie, Ferring, HAC Pharma, Janssen, Merck, Mitsubishi, Norgine, Takeda 

The Lancet Gastroenterology and Hepatology. 2020. Epub ahead of print